Clinical trial
Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia
NCT00074477 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00074477 |
|---|---|
| Title | Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 Mg-eq of Paliperidone Palmitate in Patients With Schizophrenia |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | R092670 |
| Enrollment | 250 |
| Start date | Oct 1, 2003 |
| Completion | Jul 1, 2004 |
| First posted | Dec 15, 2003 |
| Last update posted | May 24, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: